Cyberkinetics Gives Update on BrainGate Clinical Trial.

FOXBOROUGH, Mass. -- -

- Second Patient Implanted; Further Updates to Come Quarterly -

Cyberkinetics Neurotechnology Systems, Inc. (OTCBB - CYKN) today provided an update on the status of the pilot clinical trial of the BrainGate(TM) Neural Interface System, and announced its intention to provide future updates on a quarterly basis.

As of March 31, 2005, two patients have been implanted and are active in the pilot BrainGate(TM) trial. The trial is being conducted under an Investigational Device Exemption (IDE) from the FDA, which provides for implanting the BrainGate(TM) System in five patients with quadriplegia due to spinal cord injury, stroke or muscular dystrophy for a period of 12 months. The 12 month period for the first study patient will end during June 2005.

In February 2005, interim results of the pilot study of the BrainGate(TM) Neural Interface System were presented at the Association of Academic Physiatrists. This report summarized the initial findings from the first trial participant six months after implantation. The BrainGate(TM) device appears to be functioning as planned and the first participant continues to be able to use the system to control a computer using thoughts. There have been no reported adverse patient events observed in the trial to date.

The current roster of BrainGate(TM) clinical sites includes Sargent Rehabilitation Center (Warwick, RI), Spaulding Rehabilitation Center (Boston, MA) and the Rehabilitation Institute of Chicago (Chicago, IL). The Chicago site joined the trial during the most recent quarter. There is no present intention to further expand the number of sites for this initial trial.

"All of our clinical sites are actively engaged in recruiting additional patients into the BrainGate(TM) trial," said Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer. "We are making good progress in developing the next generation of BrainGate(TM) software, including patient interface upgrades and we look forward to working with our partners and with FDA to integrate those enhancements into the ongoing clinical trial."

"With this update, we are initiating a policy of providing BrainGate(TM) trial status summaries on a quarterly basis," Surgenor said. "We will continue to keep the identity and location of patients in the trial confidential, until such time as an individual patient and his or her physician decide to be identified to the public. We will also continue to report results which are clinically or scientifically meaningful through posters, presentations or publications."

About the BrainGate(TM) System

The BrainGate(TM) Neural Interface System is a proprietary, investigational brain-computer interface that consists of an internal sensor to detect brain cell activity and external processors that convert these brain signals into a computer-mediated output under the person's own control. The sensor is a tiny silicone chip about the size of a baby aspirin with one hundred electrodes, each thinner than a hair, that detect the electrical activity of neurons. The sensor is implanted on the surface of the area of the brain responsible for movement, the primary motor cortex. A small wire connects the sensor to a pedestal which extends through the scalp. An external cable connects the pedestal to a cart containing computers, signal processors and monitors which enable the study operators to determine how well a study participant can control his neural output.

About the BrainGate(TM) Pilot Study

The ongoing pilot (feasibility) study will enroll up to five quadriplegic individuals between the ages of 18 and 60 who meet the study's selection criteria. The two primary goals of the pilot clinical study are to characterize the safety profile of the device and to evaluate the quality, type, and usefulness of neural output control that patients can achieve using thoughts. Participants will undergo surgery to implant the sensor portion of the BrainGate(TM) neural interface on the area of the brain responsible for movement. During the study, they will perform tasks with the device such as attempting to control the movement of a cursor on a screen toward a specific target with their thoughts. The study is expected to last for about 12 months for each patient. At the end of the study, each participant will undergo another surgery to have the device removed or may have the option to participate in future studies. For specific information about the BrainGate(TM) clinical study please send an email to [e-mail].

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, a leader in brain-machine interface technology, is developing products to treat nervous system diseases and disorders by bringing together advances in neuroscience, computer science and engineering. Cyberkinetics' products are based on over ten years of technology development and cutting-edge neuroscience research at leading academic institutions such as Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. Cyberkinetics is publicly traded on the Over the Counter Bulletin Board under the ticker symbol, CYKN. The Company is headquartered in Foxborough, Massachusetts and conducts engineering and research in Salt Lake City, Utah. More information is available at www.cyberkineticsinc.com.

Forward Looking Safe Harbor Statement:

This press release contains forward-looking statements, including statements about plans for expansion of the BrainGate(TM) initial clinical trial and ongoing refinements of the BrainGate(TM) System. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see our filings with the Securities and Exchange Commission.